Perforating folliculitis, angioedema, hand-foot syndrome--multiple cutaneous side effects in a patient treated with sorafenib.
A patient with clear cell renal cell carcinoma was treated with sorafenib, a multikinase inhibitor, which induced a variety of cutaneous side effects. In addition to xerosis, he developed angioedema (AE), hand-foot syndrome (HFS) and perforating folliculitis (PF). The latter three occurred in a dose-dependent manner. AE was observed at the recommended daily dose of 800 mg. Dose reduction to 400 mg prevented its recurrence. At this dose level, the patient exhibited HFS, which cleared upon further reduction of the dose. While receiving 200 mg, the patient developed PF. To the best of our knowledge, this is the first description of a case of PF during treatment with sorafenib.
Wolber
Carola
C
Donauspital SMZ Ost, Department of Dermatology and Venereology, Vienna, Austria. Carola.Wolber@wienkav.at
Udvardi
Astrid
A
Tatzreiter
Georg
G
Schneeberger
Achim
A
Volc-Platzer
Beatrix
B
D000368:Aged; D000799:Angioedema / Q000139:chemically induced*; D000970:Antineoplastic Agents / Q000009:adverse effects; D001557:Benzenesulfonates / Q000009:adverse effects*; D003937:Diagnosis, Differential; D003875:Drug Eruptions / Q000175:diagnosis / Q000209:etiology*; D005499:Folliculitis / Q000139:chemically induced* / Q000175:diagnosis; D005533:Foot Dermatoses / Q000139:chemically induced* / Q000175:diagnosis; D006229:Hand Dermatoses / Q000139:chemically induced* / Q000175:diagnosis; D006801:Humans; D008297:Male; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors / Q000009:adverse effects; D011725:Pyridines / Q000009:adverse effects*; D000077157:Sorafenib; D013577:Syndrome
D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib